Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. Of 9,225 ...

Pfizer’s mRNA flu vaccine outperformed the standard flu shot in a Phase 3 clinical trial, according to results published Wednesday in the New England Journal of Medicine. The vaccine uses the same ...

Pfizer’s mRNA flu shot prevented more flu-like illness than a standard vaccine More than 18,000 adults took part in the study Side effects were mild and went away quickly FRIDAY, Nov. 21, 2025 ...

A key U.S. federal vaccine advisory panel has dropped a push against COVID mRNA vaccines, the Washington Post reported on ...

BioNTech’s CEO and his fellow co-founder will depart the biopharma by the end of the year to head up a new company focused on “next generation mRNA innovations.” Uğur Şahin, M.D., who is currently the ...

The COVID-19 pandemic brought messenger RNA (mRNA) vaccines to the forefront of global health care. After their clinical ...

The move comes as BioNTech shifts to being a multiproduct commercial biotech, allowing Ugur Sahin and Özlem Türeci to transition back into research on next-generation mRNA therapeutics.

FRIDAY, Nov. 21, 2025 (HealthDay News) — Pfizer’s mRNA flu vaccine worked better than a standard flu shot in a large Phase 3 trial, researchers reported. The results, published Nov. 19 in The New ...